{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:22:46Z","timestamp":1768080166770,"version":"3.49.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sobi, Stockholm, Sweden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12325-024-02841-w","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T10:02:05Z","timestamp":1713866525000},"page":"2307-2323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Effectiveness of Recombinant Factor\u00a0IX Fc Prophylaxis and Recombinant Factor\u00a0IX On-Demand Treatment in Patients with Haemophilia\u00a0B Without Inhibitors"],"prefix":"10.1007","volume":"41","author":[{"given":"Michal","family":"Pochopien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tytu\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aletta","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Martone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-242X","authenticated-orcid":false,"given":"Daniel","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"2841_CR1","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(6 Suppl):1\u2013158.","DOI":"10.1111\/hae.14046"},{"key":"2841_CR2","unstructured":"Abbonizio F, Biffoni M, Arcieri R, Associazione Italiana Centri Emofilia (AICE), Giampaolo A. Rapporti ISTISAN 22\/38 [in Italian]. National registry of congenital bleeding disorders. Report 2020. 2022. https:\/\/www.iss.it\/-\/rappporto-istisan-22\/38-registro-nazionale-coagulopatie-congenite.-rapporto-2020.-francesca-abbonizio-mauro-biffoni-romano-arcieri-associazione-italiana-centri-emofilia-aice-adele-giampaolo. Accessed September 2023."},{"issue":"7","key":"2841_CR3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/17474086.2018.1486704","volume":"11","author":"G Castaman","year":"2018","unstructured":"Castaman G, Linari S. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks. Expert Rev Hematol. 2018;11(7):567\u201376.","journal-title":"Expert Rev Hematol"},{"issue":"26","key":"2841_CR4","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","volume":"124","author":"PW Collins","year":"2014","unstructured":"Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor\u00a0IX in hemophilia\u00a0B: a multinational randomized phase\u00a03 trial. Blood. 2014;124(26):3880\u20136.","journal-title":"Blood"},{"issue":"3","key":"2841_CR5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/hae.12878","volume":"22","author":"K Kavakli","year":"2016","unstructured":"Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia\u00a0B. Haemophilia. 2016;22(3):381\u20138.","journal-title":"Haemophilia"},{"issue":"8","key":"2841_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","volume":"11","author":"G Castaman","year":"2018","unstructured":"Castaman G. The benefits of prophylaxis in patients with hemophilia\u00a0B. Expert Rev Hematol. 2018;11(8):673\u201383.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2841_CR7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/hae.12344","volume":"20","author":"LA Valentino","year":"2014","unstructured":"Valentino LA, Rusen L, Elezovic I, Smith LM, Korth-Bradley JM, Rendo P. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor\u00a0IX in haemophilia\u00a0B subjects. Haemophilia. 2014;20(3):398\u2013406.","journal-title":"Haemophilia"},{"issue":"24","key":"2841_CR8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","volume":"369","author":"JS Powell","year":"2013","unstructured":"Powell JS, Pasi KJ, Ragni MV, et al. Phase\u00a03 study of recombinant factor\u00a0IX Fc fusion protein in hemophilia\u00a0B. N Engl J Med. 2013;369(24):2313\u201323.","journal-title":"N Engl J Med"},{"key":"2841_CR9","first-page":"115","volume":"8","author":"E Berntorp","year":"2014","unstructured":"Berntorp E, Spotts G, Patrone L, Ewenstein BM. Advancing personalized care in hemophilia\u00a0A: ten years\u2019 experience with an advanced category antihemophilic factor prepared using a plasma\/albumin-free method. Biologics. 2014;8:115\u201327.","journal-title":"Biologics"},{"issue":"4","key":"2841_CR10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2516.2007.01521.x","volume":"13","author":"K Fischer","year":"2007","unstructured":"Fischer K, Grobbee DE, van den Berg HM. RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia. Haemophilia. 2007;13(4):345\u201350.","journal-title":"Haemophilia"},{"issue":"6","key":"2841_CR11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535\u201344.","journal-title":"N Engl J Med"},{"issue":"11","key":"2841_CR12","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","volume":"4","author":"BB Warren","year":"2020","unstructured":"Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia\u00a0A: results of the Joint Outcome Continuation Study. Blood Adv. 2020;4(11):2451\u20139.","journal-title":"Blood Adv"},{"key":"2841_CR13","doi-asserted-by":"crossref","unstructured":"Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia\u00a0A or B. Cochrane Database Syst Rev. 2011(9):CD003429.","DOI":"10.1002\/14651858.CD003429.pub4"},{"issue":"4","key":"2841_CR14","first-page":"575","volume":"12","author":"A Rocino","year":"2014","unstructured":"Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus. 2014;12(4):575\u201398.","journal-title":"Blood Transfus"},{"issue":"3","key":"2841_CR15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MBC.0000000000000885","volume":"31","author":"A Chhabra","year":"2020","unstructured":"Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia\u00a0A and B. Blood Coagul Fibrinolysis. 2020;31(3):186\u201392.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"8","key":"2841_CR16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ajh.25844","volume":"95","author":"LM Malec","year":"2020","unstructured":"Malec LM, Cheng D, Witmer CM, et al. The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. Am J Hematol. 2020;95(8):960\u20135.","journal-title":"Am J Hematol"},{"issue":"1","key":"2841_CR17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","volume":"16","author":"T Burke","year":"2021","unstructured":"Burke T, Asghar S, O\u2019Hara J, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe hemophilia\u00a0B in the United States: results from the CHESS US and CHESS US+ population surveys. Orphanet J Rare Dis. 2021;16(1):143.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2841_CR18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/2040620718796429","volume":"9","author":"T Lambert","year":"2018","unstructured":"Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295\u2013308.","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"2841_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcm6040039","volume":"6","author":"ME Mancuso","year":"2017","unstructured":"Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII\/IX concentrates. J Clin Med. 2017;6(4):39.","journal-title":"J Clin Med"},{"key":"2841_CR20","unstructured":"European Medicines Agency. BeneFIX\u00ae Summary of Product Characteristics. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benefix-epar-product-information_en.pdf. Accessed July 2023."},{"key":"2841_CR21","unstructured":"European Medicines Agency. Alprolix\u00ae Summary of Product Characteristics. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alprolix-epar-product-information_en.pdf. Accessed July 2023."},{"issue":"13","key":"2841_CR22","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood.V98.13.3600","volume":"98","author":"DA Roth","year":"2001","unstructured":"Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor\u00a0IX: safety and efficacy studies in hemophilia\u00a0B patients previously treated with plasma-derived factor\u00a0IX concentrates. Blood. 2001;98(13):3600\u20136.","journal-title":"Blood"},{"issue":"2","key":"2841_CR23","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood-2004-06-2283","volume":"105","author":"AD Shapiro","year":"2005","unstructured":"Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor\u00a0IX in previously untreated patients with severe or moderately severe hemophilia\u00a0B. Blood. 2005;105(2):518\u201325.","journal-title":"Blood"},{"issue":"2","key":"2841_CR24","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(16)30193-4","volume":"4","author":"K Fischer","year":"2017","unstructured":"Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor\u00a0IX Fc fusion protein in children with haemophilia\u00a0B (Kids B-LONG): results from a multicentre, non-randomised phase\u00a03 study. Lancet Haematol. 2017;4(2):e75\u201382.","journal-title":"Lancet Haematol"},{"issue":"13","key":"2841_CR25","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/bloodadvances.2020004085","volume":"5","author":"B Nolan","year":"2021","unstructured":"Nolan B, Klukowska A, Shapiro A, et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia\u00a0B. Blood Adv. 2021;5(13):2732\u20139.","journal-title":"Blood Adv"},{"issue":"9","key":"2841_CR26","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1007\/s12325-023-02559-1","volume":"40","author":"G Lowe","year":"2023","unstructured":"Funding E, Lowe G, Poulsen LH, et al. Real-world effectiveness of rFIXFc prophylaxis in patients with haemophilia\u00a0B switched from standard half-life therapy in three European countries. Adv Ther. 2023;40(9):3770\u201383.","journal-title":"Adv Ther"},{"issue":"6","key":"2841_CR27","first-page":"e262","volume":"26","author":"KJ Pasi","year":"2020","unstructured":"Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and sustained efficacy for up to 5\u00a0years of treatment with recombinant factor\u00a0IX Fc fusion protein in subjects with haemophilia\u00a0B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262\u201371.","journal-title":"Haemophilia"},{"issue":"1","key":"2841_CR28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14455","volume":"28","author":"J Astermark","year":"2022","unstructured":"Astermark J, Hermans C, Ezzalfani M, et al. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia\u00a0B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires. Haemophilia. 2022;28(1):18\u201326.","journal-title":"Haemophilia"},{"key":"2841_CR29","doi-asserted-by":"crossref","first-page":"204062072311707","DOI":"10.1177\/20406207231170701","volume":"14","author":"J Astermark","year":"2023","unstructured":"Astermark J, Hermans C, Ezzalfani M, et al. Recombinant factor\u00a0IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia\u00a0B: post hoc analysis of phase\u00a0III trials using patient-reported outcomes. Ther Adv Hematol. 2023;14:20406207231170700.","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"2841_CR30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/hae.12987","volume":"22","author":"KW Wyrwich","year":"2016","unstructured":"Wyrwich KW, Krishnan S, Auguste P, et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016;22(6):866\u201372.","journal-title":"Haemophilia"},{"issue":"13","key":"2841_CR31","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2009.1409","volume":"302","author":"FM Clement","year":"2009","unstructured":"Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA. 2009;302(13):1437\u201343.","journal-title":"JAMA"},{"issue":"11","key":"2841_CR32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2165\/00019053-200220110-00005","volume":"20","author":"AH Miners","year":"2002","unstructured":"Miners AH, Sabin CA, Tolley KH, Lee CA. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics. 2002;20(11):759\u201374.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"2841_CR33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","volume":"18","author":"ZY Zhou","year":"2015","unstructured":"Zhou ZY, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia\u00a0A in the United States. J Med Econ. 2015;18(6):457\u201365.","journal-title":"J Med Econ"},{"issue":"11","key":"2841_CR34","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood.V112.11.3388.3388","volume":"112","author":"C Witmer","year":"2008","unstructured":"Witmer C, Pressley R, Kulkarni R, Soucie JM, Manno CS. Intracranial hemorrhage in patients with hemophilia in the prophylaxis era. Blood. 2008;112(11):3388.","journal-title":"Blood"},{"issue":"3","key":"2841_CR35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2516.2007.01458.x","volume":"13","author":"T Lambert","year":"2007","unstructured":"Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia\u00a0B. Haemophilia. 2007;13(3):233\u201343.","journal-title":"Haemophilia"},{"issue":"4","key":"2841_CR36","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1111\/hae.13220","volume":"23","author":"A Shrestha","year":"2017","unstructured":"Shrestha A, Eldar-Lissai A, Hou N, Lakdawalla DN, Batt K. Real-world resource use and costs of haemophilia\u00a0A-related bleeding. Haemophilia. 2017;23(4):e267\u201375.","journal-title":"Haemophilia"},{"issue":"2","key":"2841_CR37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1365-2516.2001.00494.x","volume":"7","author":"P Chowdary","year":"2001","unstructured":"Chowdary P, Dasani H, Jones JA, et al. Recombinant factor\u00a0IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia. 2001;7(2):140\u20135.","journal-title":"Haemophilia"},{"issue":"3","key":"2841_CR38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","volume":"123","author":"J Mahlangu","year":"2014","unstructured":"Mahlangu J, Powell JS, Ragni MV, et al. Phase\u00a03 study of recombinant factor VIII Fc fusion protein in severe hemophilia\u00a0A. Blood. 2014;123(3):317\u201325.","journal-title":"Blood"},{"issue":"3","key":"2841_CR39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","volume":"26","author":"B Nolan","year":"2020","unstructured":"Nolan B, Mahlangu J, Pabinger I, et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia\u00a0A: final results from the ASPIRE extension study. Haemophilia. 2020;26(3):494\u2013502.","journal-title":"Haemophilia"},{"key":"2841_CR40","unstructured":"I. Stat. Mortality life tables: deaths of resident population. 2020. http:\/\/dati.istat.it\/Index.aspx?DataSetCode=DCIS_MORTALITA1&Lang=en. Accessed October 2021."},{"issue":"1","key":"2841_CR41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1478-7547-12-5","volume":"12","author":"G Kourlaba","year":"2014","unstructured":"Kourlaba G, Maniadakis N, Andrikopoulos G, Vardas P. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resour Alloc. 2014;12(1):5.","journal-title":"Cost Eff Resour Alloc"},{"key":"2841_CR42","unstructured":"Official Gazette. Supplemento Ordinario n.8 Alla Gazzetta Ufficiale n.23 of 28\u201301\u20132013 \u2013 Allegato 3 Prestazioni di Assistenza Specialistica Ambulatoriale. 2013. https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2013\/01\/28\/23\/so\/8\/sg\/pdf. Accessed September 2023."},{"key":"2841_CR43","unstructured":"University Hospital Federico II Diagnostic Therapeutic Assistance Pathway. Azienda Universitaria Ospedaliera \u201cFederico II\u201d Percorso Diagnostico Terapeutico Assistenziale (PDTA 2021) Per La Gestione di Pazienti con Malattie Emorragiche Congenite (MEC) SIA In Routine Che In Emergenza-Urgenza. 2021. https:\/\/www.policlinico.unina.it\/archivio_documenti\/2021\/DEL\/del203_all2.pdf. Accessed September 2023."},{"key":"2841_CR44","unstructured":"ARAN Agenzia. 2022. https:\/\/www.aranagenzia.it\/attachments\/article\/9016\/CCNL%20comparto%20SANITA\u2019%20definitivo_sito%20.pdf. Accessed October 2022."},{"key":"2841_CR45","unstructured":"Official Gazette. Supplemento Ordinario n.8 Alla Gazzetta Ufficiale n.23 of 28\u201301\u20132013 \u2013 Allegato 1 Tariffe Dell Prestazioni Di Assistenza Ospedaliera Per Acuti, Per Tipo Di Ricovero. 2013. https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2013\/01\/28\/23\/so\/8\/sg\/pdf. Accessed September 2023."},{"key":"2841_CR46","unstructured":"Annual Report on Hospitalisation Activity. Rapporto Annuale Sull\u2019attivit\u00e0 Di Ricovero Ospedaliero \u2013 Dati SDO 2019. 2019. https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_3002_allegato.pdf. Accessed September 2023."},{"key":"2841_CR47","unstructured":"European Commission. What is \u2018human effort\u2019 (person-months) and how to calculate it? 2019. https:\/\/ec.europa.eu\/newsroom\/just\/items\/643967\/en. Accessed September 2023."},{"key":"2841_CR48","unstructured":"JobPricing. Salary outlook. 2021. https:\/\/www.jobpricing.it\/blog\/project\/salary-outlook-primaedizione\/. Accessed October 2022."},{"issue":"1","key":"2841_CR49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s13023-021-02152-1","volume":"16","author":"T Burke","year":"2021","unstructured":"Burke T, Asghar S, O\u2019Hara J, Chuang M, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe haemophilia\u00a0B in adults receiving factor\u00a0IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet J Rare Dis. 2021;16(1):521.","journal-title":"Orphanet J Rare Dis"},{"issue":"5 Suppl","key":"2841_CR50","first-page":"s126","volume":"22","author":"SL Chen","year":"2016","unstructured":"Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5 Suppl):s126\u201333.","journal-title":"Am J Manag Care"},{"key":"2841_CR51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JBM.S43734","volume":"4","author":"K Saxena","year":"2013","unstructured":"Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med. 2013;4:49\u201356.","journal-title":"J Blood Med"},{"issue":"4","key":"2841_CR52","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","volume":"9","author":"A Gringeri","year":"2011","unstructured":"Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia\u00a0A (the ESPRIT Study). J Thromb Haemost. 2011;9(4):700\u201310.","journal-title":"J Thromb Haemost"},{"issue":"6 Suppl","key":"2841_CR53","first-page":"S123","volume":"21","author":"DR Dalton","year":"2015","unstructured":"Dalton DR. Hemophilia in the managed care setting. Am J Manag Care. 2015;21(6 Suppl):S123\u201330.","journal-title":"Am J Manag Care"},{"issue":"3","key":"2841_CR54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/hae.14525","volume":"28","author":"E Berntorp","year":"2022","unstructured":"Berntorp E, LeBeau P, Ragni MV, et al. Quality of life in a large multinational haemophilia\u00a0B cohort (the B-Natural study) - unmet needs remain. Haemophilia. 2022;28(3):453\u201361.","journal-title":"Haemophilia"},{"issue":"6","key":"2841_CR55","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30264","volume":"70","author":"T Zhou","year":"2023","unstructured":"Zhou T, Wang S, Zhang Y, Wu R, Li H. Cost-effectiveness analysis of recombinant factor\u00a0IX Fc fusion protein compared with recombinant factor\u00a0IX for the treatment of moderate-severe to severe hemophilia\u00a0B in China. Pediatr Blood Cancer. 2023;70(6):e30264.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2841_CR56","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/hae.13185","volume":"23","author":"A Coppola","year":"2017","unstructured":"Coppola A, D\u2019Ausilio A, Aiello A, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia\u00a0A in Italy. Haemophilia. 2017;23(3):422\u20139.","journal-title":"Haemophilia"},{"issue":"1","key":"2841_CR57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/16078454.2021.1885123","volume":"26","author":"Z Zahedi","year":"2021","unstructured":"Zahedi Z, Karimi M, Keshavarz K, Haghpanah S, Ravangard R. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia\u00a0A patients under 12\u00a0years old in southern Iran. Hematology. 2021;26(1):240\u20138.","journal-title":"Hematology"},{"key":"2841_CR58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CEOR.S16670","volume":"3","author":"GL Colombo","year":"2011","unstructured":"Colombo GL, Di Matteo S, Mancuso ME, Santagostino E. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia\u00a0A. Clinicoecon Outcomes Res. 2011;3:55\u201361.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"2841_CR59","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/hae.12121","volume":"19","author":"A Farrugia","year":"2013","unstructured":"Farrugia\u00a0A, Cassar J, Kimber MC, et al. Treatment for life for severe haemophilia\u00a0A\u2014a cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia. 2013;19(4):e228-38.","journal-title":"Haemophilia"},{"issue":"2","key":"2841_CR60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/hae.12009","volume":"19","author":"AH Miners","year":"2013","unstructured":"Miners AH. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia. 2013;19(2):174\u201380.","journal-title":"Haemophilia"},{"issue":"8","key":"2841_CR61","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, Slaap B, Herdman M, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245\u201357.","journal-title":"Eur J Health Econ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02841-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02841-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02841-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T13:23:38Z","timestamp":1716902618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02841-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2841"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02841-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Micha\u0142 Pochopien, Anna Tytu\u0142a and Mondher Toumi were previously employees of Creativ-Ceutical, a consultancy company that received funding from Sobi for this research. Aletta Falk, Nicoletta Martone, Zalmai Hakimi and Daniel Eriksson are employees of and shareholders in Sobi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}